GSK

Johnson & Johnson has decided not to enter the obesity market, focusing instead on cancer research and acquiring Halda Therapeutics for prostate cancer therapy. The FDA approved GSK's antibiotic Utebzi for treating drug-resistant infections, and the article mentions an FDA review of Moderna's flu shot.

GSK acquired Nuvalent, a biotech company with two drugs under FDA review for targeting genetic mutations in lung cancer, for $10.6 billion. Approval decisions for the drugs are expected later this year.

The U.S. stock market rose as AI stocks rebounded from recent losses and oil prices declined. The S&P 500 gained 0.2%, the Dow Jones Industrial Average increased 0.4%, and J.M. Smucker surged 11.5% due to stronger-than-expected profits. Airlines like United and Delta also gained as oil prices fell 3.3%.

GSK acquired Nuvalent, a cancer drug developer, in a $10.6 billion deal to expand its oncology portfolio, while Merck and Gilead Sciences reported success in final-stage trials for a once-weekly HIV pill combining their experimental drugs. The GSK acquisition highlights ongoing biopharma industry consolidation as companies bolster pipelines amid generic competition.

GSK acquired cancer drugmaker Nuvalent for $10.6 billion, reflecting the rising significance of cancer in the pharmaceutical market. The move aims to leverage Nuvalent’s antibody therapies to compete with companies like Merck, as cancer becomes more prevalent and treatable due to aging populations and advancements in detection and treatment.

GSK is acquiring lung cancer biotech Nuvalent in its largest deal in over a decade. The all-cash transaction provides GSK with two late-stage lung cancer drugs under FDA review.

GSK, a U.K. pharmaceutical company, announced a $10.6 billion acquisition of Nuvalent, a U.S.-listed biotech firm, marking its largest purchase in eight years to strengthen its cancer portfolio.

British drugmaker GSK, led by new CEO Luke Miels, has agreed to acquire US-based cancer treatment firm Nuvalent for $10.6 billion. The deal aims to strengthen GSK's oncology portfolio, with Nuvalent developing three late-stage lung cancer medications.

British drugmaker GSK has agreed to acquire US-based cancer treatment company Nuvalent for $10.6 billion to expand its oncology portfolio. The deal includes Nuvalent's three late-stage lung cancer medications.

GSK has agreed to buy Nuvalent for $10.6 billion. The acquisition is valued at $10.6 billion.

GSK agreed to acquire Nuvalent, a cancer-focused biotech company, for $10.6 billion in a cash deal. The transaction includes a 26% premium over Nuvalent’s 30-day average share price, with GSK paying $124 per share and spending approximately $9.4 billion in cash.

GSK is in talks to acquire cancer biotech Nuvalent for more than $9 billion. The deal would rank as one of the UK drugmaker’s largest as biotech M&A activity accelerates this year.

GSK is in discussions to acquire Nuvalent for more than $9 billion, according to the Financial Times. The potential deal could significantly expand GSK's portfolio.

An experimental hepatitis B drug called bepirovirsen may offer a 'functional cure' for some patients, with 20% of trial participants maintaining undetectable virus levels after stopping treatment. Developed by GSK and Ionis Pharmaceuticals, the drug is under fast-track FDA review and shows potential to address chronic hepatitis B, which affects over 250 million people globally.

Scientists report early progress in engineered heart patches and GSK announces a functional cure for hepatitis B. The article also highlights potential drug launches tied to President Trump's 'most-favored nation' claims and previews the upcoming ASCO meeting in Chicago.

An experimental hepatitis B treatment, GSK’s bepirovirsen, achieved functional cures in 20% and 19% of patients in Phase 3 trials, significantly outperforming current treatments that achieve 1-3% success rates. The drug showed no functional cures in placebo groups, offering hope for a more effective solution to a disease affecting 250-300 million people globally.

GSK reported early trial results showing Mo-Rez reduced or eliminated tumors in 62% of ovarian cancer patients and 67% of endometrial cancer patients. The CEO, Luke Miels, is advancing drug development efforts for the potential blockbuster treatment.